Comparison of chemoembolization with CalliSpheres
CalliSpheres microspheres
chemoembolization
hepatocellular carcinoma
predictive factor
survival
treatment response
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
09
2018
accepted:
27
06
2019
entrez:
28
2
2020
pubmed:
28
2
2020
medline:
28
2
2020
Statut:
epublish
Résumé
This study aimed to compare the efficacy and safety between transarterial chemoembolization (TACE) with CalliSpheres Three hundred and thirty-five HCC patients receiving CSM-TACE or cTACE were consecutively enrolled in this multi-center, retrospective cohort study, and then divided into CSM-TACE group and cTACE group accordingly. Complete response (CR), objective response (ORR) and disease control response (DCR) was assessed according to mRECIST criteria at 1 month (M1), 3 months(M3) and 6 months(M6) after treatment. Progression-free survival (PFS) and overall survival (OS) were assessed. Liver function indexes and adverse events (AEs) were also evaluated. CR at M3 ( CSM-TACE presents with a better treatment response and similar survival profile compared with cTACE in HCC patients.
Identifiants
pubmed: 32104076
doi: 10.2147/CMAR.S187203
pii: 187203
pmc: PMC7020935
doi:
Types de publication
Journal Article
Langues
eng
Pagination
941-956Informations de copyright
© 2020 Liang et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Eur Radiol. 2016 Jun;26(6):1640-8
pubmed: 26455721
Hepatology. 2002 May;35(5):1164-71
pubmed: 11981766
J Vasc Interv Radiol. 2013 May;24(5):647-54
pubmed: 23384831
Eur Radiol. 2017 Feb;27(2):526-535
pubmed: 27277261
Zhonghua Gan Zang Bing Za Zhi. 2016 Jul 20;24(7):549-551
pubmed: 27784439
J Gastroenterol Hepatol. 2002 Jan;17(1):52-8
pubmed: 11895553
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Clin Gastroenterol Hepatol. 2007 Sep;5(9):1100-8
pubmed: 17627902
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Cardiovasc Intervent Radiol. 2010 Feb;33(1):41-52
pubmed: 19908093
AJR Am J Roentgenol. 2017 Oct;209(4):722-732
pubmed: 28705059
AJR Am J Roentgenol. 2015 Oct;205(4):764-73
pubmed: 26397324
J Dig Dis. 2016 Aug;17(8):510-517
pubmed: 27384075
Clin Res Hepatol Gastroenterol. 2017 Feb;41(1):75-85
pubmed: 27350573
Hepatology. 2010 Aug;52(2):762-73
pubmed: 20564355
Lancet. 2002 May 18;359(9319):1734-9
pubmed: 12049862
Hepatobiliary Pancreat Dis Int. 2016 Oct;15(5):493-498
pubmed: 27733318
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818759878
pubmed: 29739274
J Vasc Interv Radiol. 2017 Sep;28(9):1224-1231.e2
pubmed: 28688815
Drug Deliv. 2017 Nov;24(1):1011-1017
pubmed: 28660787
Exp Ther Med. 2018 Feb;15(2):1479-1483
pubmed: 29434732
J Vasc Interv Radiol. 2004 Nov;15(11):1209-18
pubmed: 15525739
Asian Pac J Cancer Prev. 2016;17(8):4037-41
pubmed: 27644658
World J Hepatol. 2017 Jun 28;9(18):808-814
pubmed: 28706579
Mol Cancer. 2015 Jan 27;14:10
pubmed: 25622857
J Gastroenterol Hepatol. 2017 Feb;32(2):487-496
pubmed: 27503585